Boulder’s Enveda Biosciences raises $68M

BOULDER — Enveda Therapeutics Inc. has raised $68 million in a combined debt and equity fundraising round and is on track to unveil several clinical treatment candidates in the new year. 

The company, which does business as Enveda Biosciences, uses artificial intelligence to identify potential therapeutics that occur in nature. Enveda is working on pre-clinical research into treatments for nonalcoholic steatohepatitis and Wilson’s Disease, two conditions where fat and copper build up in the liver.

The Series B round, which comes on the heels of a 2021 Series A round that raised $51 million, was led by Dimension Ventures, and “was…